The Safety and Efficacy of MRG003 With or Without Putrelimab in Recurrent or Metastatic Salivary Gland Cancer: a Single-center, Open-label Cohort Study
Clinical trial NCT07464366 · RECRUITING
Trial details
- NCT number
- NCT07464366
- Sponsor
- Ji Dongmei
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-03-19
- Primary completion
- 2028-05-30
- Enrollment
- 90
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.